RxDoctor Payments Data

Courtney Maniatis, DO

Internal Medicine · Woodstock, GANPI 1780881862

Payments from drug & device makers

$232in general payments, 2019–2025

Across 14 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$62
  • Amgen$33
  • Lilly USA, LLC$24
  • Abbott$22
  • Exact Sciences$18
  • GSK$17
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$22095%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$232 in reported general payments places this provider in the 40th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$105,834
Medicare patients
306
Services billed
1,451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$54,043
MounjaroTirzepatide37$42,430
EliquisApixaban39$36,242
JanuviaSitagliptin Phosphate31$25,067
JardianceEmpagliflozin27$24,046
TrulicityDulaglutide20$17,398
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,658
GemtesaVibegron18$11,396
MyrbetriqMirabegron12$9,227
Breo ElliptaFluticasone/Vilanterol13$9,173
SynthroidLevothyroxine Sodium71$6,340
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$5,601
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$4,535
Levothyroxine Sodium255$2,067
Atorvastatin Calcium242$1,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$24$59,82857 claims
Novo NordiskOzempic$62$54,04335 claims
GSKTrelegy Ellipta, Breo Ellipta$17$25,83131 claims
Boehringer IngelheimJardiance$12$24,04627 claims
AbbVieSynthroid$13$6,34071 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Woodstock

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →